Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.
TLDR
In this article, inflammatory cytokines are considered to be responsible for a highly deleterious pathophysiologic process: the phenotypic transformation of polycythemia vera (PV) or essential thrombocythemia (ET), and the equivalent emergence of primary myelofibrosis (PMF).Abstract:
Myeloid neoplasms, including acute myeloid leukemia (AML), myeloproliferative neoplasms (MPNs), and myelodysplastic syndromes (MDS), feature clonal dominance and remodeling of the bone marrow niche in a manner that promotes malignant over non-malignant hematopoiesis. This take-over of hematopoiesis by the malignant clone is hypothesized to include hyperactivation of inflammatory signaling and overproduction of inflammatory cytokines. In the Ph-negative MPNs, inflammatory cytokines are considered to be responsible for a highly deleterious pathophysiologic process: the phenotypic transformation of polycythemia vera (PV) or essential thrombocythemia (ET) to secondary myelofibrosis (MF), and the equivalent emergence of primary myelofibrosis (PMF). Bone marrow fibrosis itself is thought to be mediated heavily by the cytokine TGF-β, and possibly other cytokines produced as a result of hyperactivated JAK2 kinase in the malignant clone. MF also features extramedullary hematopoiesis and progression to bone marrow failure, both of which may be mediated in part by responses to cytokines. In MF, elevated levels of individual cytokines in plasma are adverse prognostic indicators: elevated IL-8/CXCL8, in particular, predicts risk of transformation of MF to secondary AML (sAML). Tumor necrosis factor (TNF, also known as TNFα), may underlie malignant clonal dominance, based on results from mouse models. Human PV and ET, as well as MF, harbor overproduction of multiple cytokines, above what is observed in normal aging, which can lead to cellular signaling abnormalities separate from those directly mediated by hyperactivated JAK2 or MPL kinases. Evidence that NFκB pathway signaling is frequently hyperactivated in a pan-hematopoietic pattern in MPNs, including in cells outside the malignant clone, emphasizes that MPNs are pan-hematopoietic diseases, which remodel the bone marrow milieu to favor persistence of the malignancy. Clinical evidence that JAK2 inhibition by ruxolitinib in MF neither reliably reduces malignant clonal burden nor eliminates cytokine elevations, suggests targeting cytokine mediated signaling as a therapeutic strategy, which is being pursued in new clinical trials. Greater knowledge of inflammatory pathophysiology in MPNs can therefore contribute to the development of more effective therapy.read more
Citations
More filters
Journal ArticleDOI
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
Lionel Ades,Larisa Girshova,Vadim A Doronin,María Díez-Campelo,David Valcárcel,Suman Kambhampati,Nora Viniou,Dariusz Woszczyk,R. de Paz Arias,Argiris Symeonidis,Achilles Anagnostopoulos,Eduardo Munhoz,Uwe Platzbecker,Valeria Santini,Robert Fram,Ying Yuan,Sharon Friedlander,Douglas V. Faller,Mikkael A. Sekeres +18 more
TL;DR: The results underscore the importance of large, randomized controlled trials in these heterogeneous myeloid diseases and the value of remaining on therapy >3 cycles.
Journal ArticleDOI
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
TL;DR: In this paper , the PD-1/PD-L1 pathway activated in immune microenvironment, the milieu of BM shift to immunosuppressive, contributing to a clonal evolution of blasts.
Journal ArticleDOI
Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study.
Naveen Pemmaraju,Jacqueline S. Garcia,Jalaja Potluri,Jason G. Harb,Yan Sun,P. Soo Jung,Q. Qin,Srinivas K. Tantravahi,Srdan Verstovsek,Claire N. Harrison +9 more
TL;DR: This article showed that the addition of navitoclax to ruxolitinib induced a 35% or greater reduction in spleen volume (SVR35) and reduced symptoms in patients with myelofibrosis no longer benefiting from ruxolaxinib.
Journal ArticleDOI
Defining disease modification in myelofibrosis in the era of targeted therapy
TL;DR: In this article , the authors discuss recent clinical trial data of agents in development and dissect the potential for novel end points to act as disease modifying parameters, using the rationale garnered from latest clinical and scientific evidence, the authors propose a definition of disease modification in myelofibrosis.
Journal ArticleDOI
BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis.
Srdan Verstovsek,Haifa Kathrin Al-Ali,John Mascarenhas,Andrew C. Perkins,Alessandro M. Vannucchi,Sanjay R. Mohan,Bart L. Scott,Dariusz Woszczyk,Steffen Koschmieder,Regina Garcia-Delgado,Rejtő László,Jesse McGreivy,Wayne Rothbaum,Jean-Jacques Kiladjian +13 more
TL;DR: Navtemadlin (KRT-232) as mentioned in this paper restores p53 activity to drive apoptosis of wild-type TP53 tumor cells by inducing expression of pro-apoptotic Bcl-2 family proteins.
References
More filters
Journal ArticleDOI
Targeting NF-κB in hematologic malignancies
TL;DR: NF-κB inhibitory molecules may be clinically useful, either as single therapeutic agents or in combination with classical chemotherapeutic agents, for the treatment of hematological malignancies.
Journal ArticleDOI
Autoimmunity and the risk of myeloproliferative neoplasms.
TL;DR: A prior history of any autoimmune disease is found to be associated with a significantly increased risk of myeloproliferative neoplasms and the risk of MPNs associated with prior autoimmune diseases is modest but statistically significant.
Journal ArticleDOI
IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells
Carolina Schinke,Orsolya Giricz,Weijuan Li,Aditi Shastri,Shanisha Gordon,Laura Barreyro,Tushar D. Bhagat,Sanchari Bhattacharyya,Nandini Ramachandra,Matthias Bartenstein,Andrea Pellagatti,Jacqueline Boultwood,Amittha Wickrema,Yiting Yu,Britta Will,Sheng Wei,Ulrich Steidl,Amit Verma +17 more
TL;DR: It is demonstrated that the IL8 receptor CXCR2 is an adverse prognostic factor in MDS/AML and is a potential therapeutic target against immature leukemic stem cell-enriched cell fractions in M DS and AML.
Journal ArticleDOI
Constitutive NF-kappaB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway.
TL;DR: It is demonstrated that Ras activation is an important pathway for triggering the NF-κB pathway in AML cells and Intervening in aberrant signaling pathway provides a rational approach for in vivo targeting ofAML cells.
Journal ArticleDOI
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis
Michael W. Deininger,Jerald P. Radich,Timothy Burn,Reid Huber,Dilan Paranagama,Srdan Verstovsek +5 more
TL;DR: Allele burden reductions were greater in patients with shorter disease duration, which suggests a potential benefit of earlier treatment, and reductions in allele burden from baseline with ruxolitinib treatment that correlated with spleen volume reductions.